Home » Stocks » DYN

Dyne Therapeutics, Inc. (DYN)

Stock Price: $19.40 USD -0.83 (-4.10%)
Updated Feb 25, 2021 3:59 PM EST - Market closed
After-hours: $19.00 -0.40 (-2.06%) Feb 25, 7:35 PM
Market Cap 1.07B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 6.92M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $19.40
Previous Close $20.23
Change ($) -0.83
Change (%) -4.10%
Day's Open 20.17
Day's Range 19.10 - 20.86
Day's Volume 225,533
52-Week Range 15.60 - 32.32


Hide News
GlobeNewsWire - 1 month ago

WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people livi...

GlobeNewsWire - 1 month ago

- In Vivo Model Developed by Dyne Sets New Standard for Evaluating  Pharmacodynamics in DM1 -

About DYN

Dyne Therapeutics, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.

Pharmaceutical Preparation Manufacturing
IPO Date
Sep 17, 2020
Joshua T. Brumm
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DYN stock is "Buy." The 12-month stock price forecast is 36.40, which is an increase of 87.63% from the latest price.

Price Target
(87.63% upside)
Analyst Consensus: Buy